| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Adenine nucleotide translocase (ANT); mitochondrial permeability transition pore. Agaricic acid induces mitochondrial permeability transition through its interaction with adenine nucleotide translocase (ANT). It promotes the efflux of accumulated Ca2+, disruption of transmembrane potential, and mitochondrial swelling. The compound's effects on mitochondria are dependent on membrane fluidity.
|
|---|---|
| ln Vitro |
Agaricic acid induces mitochondrial permeability transition in vitro through its interaction with adenine nucleotide translocase. It promotes the efflux of accumulated Ca2+, disruption of transmembrane potential, and mitochondrial swelling. The compound is used to regulate lipid metabolism. Its effects on mitochondria have been characterized in various in vitro assays using isolated mitochondria.
|
| ln Vivo |
In vivo, Agaricic acid has been used to regulate lipid metabolism. It may have effects on mitochondrial function and energy metabolism. However, detailed in vivo studies are limited. The compound is primarily used as a research tool to study mitochondrial function and adenine nucleotide translocase.
|
| Enzyme Assay |
In vitro mitochondrial assays for Agaricic acid involve isolating mitochondria from tissues and treating them with Agaricic acid at varying concentrations (typically 1-100 µM). Mitochondrial swelling is measured spectrophotometrically by monitoring changes in absorbance at 540 nm. Calcium efflux is measured using calcium-sensitive fluorescent indicators. Transmembrane potential is measured using fluorescent dyes such as JC-1 or tetraphenylphosphonium.
|
| Cell Assay |
Cellular assays for Agaricic acid involve culturing cells and treating them with the compound at varying concentrations (typically 1-100 µM). Mitochondrial function is assessed by measuring mitochondrial membrane potential using fluorescent dyes, ATP levels using luciferase-based assays, and reactive oxygen species production using fluorescent probes. Cell viability is assessed using standard assays such as MTT.
|
| Animal Protocol |
In vivo animal studies for Agaricic acid are not extensively documented. When performed, they typically involve administration in rodent models to assess effects on lipid metabolism or mitochondrial function. The compound is typically administered orally or via injection. Dosing regimens vary depending on the study objectives.
|
| ADME/Pharmacokinetics |
Agaricic acid has a molecular weight of 416.55 g/mol and a molecular formula of C22H40O7. It appears as an odorless, almost tasteless crystalline powder. The anhydrous form has a melting point of 142°C (dec). The compound is freely soluble in boiling water and alkalies, and soluble in chloroform and ether. It should be stored under dry conditions.
|
| Toxicity/Toxicokinetics |
Agaricic acid is generally considered safe for research use at appropriate concentrations. Comprehensive toxicological data are limited. The compound is a natural product derived from fungi and is not known to be highly toxic. It is intended for research use only and is not approved for human therapeutic applications. Standard laboratory safety precautions should be taken when handling the compound.
|
| References | |
| Additional Infomation |
Agaric acid is a carbonyl compound. It has been reported that agaric acid has been found in Ischnoderma benzoinum, and relevant data are available for reference.
Agaricic acid (agaric acid) is a fungal-derived tricarboxylic fatty acid that induces mitochondrial permeability transition through interaction with adenine nucleotide translocase. It promotes calcium efflux and mitochondrial swelling. The compound is used as a research tool to study mitochondrial function. It is not approved for clinical use and is available for research purposes only. |
| Molecular Formula |
C22H40O7
|
|---|---|
| Molecular Weight |
416.5488
|
| Exact Mass |
416.277
|
| CAS # |
666-99-9
|
| PubChem CID |
12629
|
| Appearance |
White to off-white solid powder
|
| Density |
1.115g/cm3
|
| Boiling Point |
509.3ºC at 760 mmHg
|
| Melting Point |
142° (dec)
|
| Flash Point |
275.9ºC
|
| Index of Refraction |
1.501
|
| LogP |
4.849
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
20
|
| Heavy Atom Count |
29
|
| Complexity |
478
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
HZLCGUXUOFWCCN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H40O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18(20(25)26)22(29,21(27)28)17-19(23)24/h18,29H,2-17H2,1H3,(H,23,24)(H,25,26)(H,27,28)
|
| Chemical Name |
2-hydroxynonadecane-1,2,3-tricarboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~300.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (4.99 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4007 mL | 12.0034 mL | 24.0067 mL | |
| 5 mM | 0.4801 mL | 2.4007 mL | 4.8013 mL | |
| 10 mM | 0.2401 mL | 1.2003 mL | 2.4007 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
